Marksans Pharma Ltd share price target 2023, 2024, 2025, till 2030

Rate this post

Hey, are you looking for the Marksans Pharma Ltd share price target for 2023, 2024, 2025 till 2030 then you are in the right place, in this article we are analyzing Marksans Pharma Ltd based on its fundamentals and technicals so we can get a clear picture of the future growth of the Company.

Overview of the markSans Pharma Ltd.

Marks and Pharma Ltd company is a pharmaceutical company engaged in manufacturing and sales of generic drugs throughout India as well as all over the world.

Marksans Pharma Ltd was incorporated in 1992, and its headquarter is located in Mumbai the present Chairman of the company is Mr. Mark Saldanha.

The company is now present in active pharmaceuticals API formulations and biopharmaceuticals.

The engagement of the company in the production of prescription drugs caters to areas like Oncology, Antidiabetic, gastroenterology, cardiovascular pain management, gynecology, and other drugs.

The company has 4 Research and Development centers, and in the company overall 1412 employees are working. Three plants were approved by US FDA, UK MHRA, and TGA.

Business areas of Marksans Pharma Ltd.

Research and Development:

The company is involved in R&D to innovate new drugs, Molecular Biology, Toxicology Pharmacology pharmacokinetics.

Formulation:

The company is engaged in manufacturers of non-sterile liquids, tablets, ointments, and powder products.

APIs:

The company has two API manufacturing units located in Pune and presently has a manufacturing capacity of 1140 TPA.

Fundamentals of the Marksans Pharma Ltd:

Market Cap3,527.88 Cr.
No. Of Shares45.32 Cr.
PE33.13
PB2.95
Dividend Yield0.32%
Cash Reserve224.05 Cr.
DEBT5 Cr.
Book Value26.35
EPS2.35
ROE16.11%
ROCE19.91%
Sales Growth9.80%
Profit Growth5.70%
Marksans Fundamentals

Fundamental Analysis of Marksans Pharma Ltd.

The sales growth of the company for the last year is 9.8% and for the last 3 years is 15.78% and the for last five years is 24.98% that indicates companies regularly increase their sales.

The company’s profit growth for the last year is 5.7% and for the last three years is 33.59% and for the last 5 years is 55.21% that indicates the company is stably giving a regular profit.

The company has 5 CR debit and a cash reserve is 224.05 CR which indicates the company is Virtually debt free. The company’s debt-to-equity ratio is 0.01% which is negligible.

The company’s interest cover ratio is 36.44 which indicates the company can pay interest on its outstanding debt easily.

Marksans Pharma Ltd. Shareholding Pattern:

Marksans Share Holding Pattern

Promoter holding in the company is nearly 43.85% which indicates the promoter believes that the company will grow in the future.

FII and DII Holding in the company is 15.11% and 1.47% which indicate that smart money believes that can grow in the future and generate a good return.

The public holding in the company is 39.58% which may create more liquidity in the stock market in a panic situation.

The promoters pledging of their shares is zero.

Technical Analysis of Marksans Pharma Ltd.

Marksans Pharma monthly chart

From the long-term investment point of view, we are taking monthly charts to analyze the stock and understand the trend of the stock. The stock is trading at 78.40 RS on 21 April 2023. The stock is in an uptrend on the monthly chart.

If the stock sustains above 90 then its first target will be 113 and second target will be 183 and the third target will be 225.

The major support for the stock is the first support is 70, the second support is 57, and the third support is 44.

The major resistance for the stock is the first resistance is 89 and the second resistance is 110 and 3rd resistance is 150.

Marksans Pharma Ltd. Share Price Target.

YearMinimumMaximum
20237096
202489125
2025118183
2026165295
2027272406
2028389555
2029540690
2030672821
Marksans Pharma share price Target/forecast/prediction

Marksans Pharma Ltd. Share Price Target/Prediction/Forecast.

Read More: Morepen Laboratories Share price

Marksans Pharma Ltd. Share Price Target 2023

Marks and Pharma Limited sales are increasing yearly which indicates the stock price will increase in the future the minimum price will be 70 and the maximum price will be 96.

Marksans Pharma Ltd. Share Price Target 2024

The company spends a lot of money on its R&D that could help expand its business and innovate new technology and Drugs so the minimum target will be 89 and the maximum will be 125.

Marksans Pharma Ltd. Share Price Target 2025

Marksans Pharma Ltd.’s Share Price Target for 2025 will be a minimum of 118 and a maximum will be 183.

Marksans Pharma Ltd. Share Price Target 2026

Marksans Pharma Ltd.’s Share Price Target for 2026 will be a minimum of 165 and a maximum will be 295.

Marksans Pharma Ltd. Share Price Target 2027

Marksans Pharma Ltd.’s Share Price Target for 2027 will be a minimum of 272 and a maximum will be 406.

Marksans Pharma Ltd. Share Price Target 2028

Marksans Pharma Ltd.’s Share Price Target for 2028 will be a minimum of 389 and a maximum will be 555.

Marksans Pharma Ltd. Share Price Target 2029

Marksans Pharma Ltd.’s Share Price Target for 2029 will be a minimum of 540 and a maximum will be 690.

Marksans Pharma Ltd. Share Price Target 2030

Marksans Pharma Ltd.’s Share Price Target for 2030 will be a minimum of 672 and a maximum will be 821.

Conclusion:

Marksans Pharma Ltd. is the fastest-growing pharma company in generic medicine and the company has strong fundaments and technicals. The company is debt free and it also pays dividends to its investors the company is also interested in investing in R&D. Over the balance of the company is good so before investment check all market conditions and sector trends. if you like this article then comment below and share this article with your family and friends and give your feed to us.

Read More: Aarti Drugs Share Price Target

FAQ Of Marksans Pharma:

Is Marksans Pharma debt free?

The company has 5 CR debit and a cash reserve is 224.05 CR which indicates the company is Virtually debt free. The company’s debt-to-equity ratio is 0.01% which is negligible.

Is Marksans Pharma a good stock?

Marksans Pharma Ltd. is the fastest-growing pharma company in generic medicine and the company has strong fundaments and technicals. The company is debt free and it also pays dividends to its investors the company is also interested in investing in R&D. Over the balance of the company is good

What will be the share price of Marksans in 2023?

Marks and Pharma Limited sales are increasing yearly which indicates the stock price will increase in the future the minimum price will be 70 and the maximum price will be 96.

Leave a Comment